LOS ANGELES, CA, (NAMC) - It looks like both Millipore Corporation (NYSE: MIL) and Serologicals Corporation (NASDAQ: SERO) have come to terms as both companies have signed a definitive agreement in which Millipore will acquire Serologicals for $31.55 per share in an all cash transaction.

The acquisition could potentially put Millipore into the position of being a $1.4 billion a year company. The strategic combination of Millipore and Serologicals could significantly strengthen Millipore's Bioscience Division by giving it leading positions in high growth segments such as drug discovery products and services, antibodies, cell biology reagents, and stem cell research.

David Kingston
Business News Correspondent
NAMC Newswire
www.namcnewswire.com

Click here for your free subscription to Wall Street to Main Street from the NAMC Newswire, delivered to investors daily. www.namcnewswire.com

This article can be republished either online or in print as long as credit is given to the author and the NAMC Newswire.
 
NAMC Newswire articles can now be listened to on StreetIQ.com
http://www.streetiq.com/dir/NAMC.shtml

To keep up to date with companies that we report on just register to receive the FREE Wall Street to Main Street Daily Newsletter. We feature companies that trade on the NYSE, AMEX, NASDAQ, OTCBB and Overseas, Keeping our readers informed daily. Just go to our site and register, it’s simple and free, www.namcnewswire.com/newsletter . Also be sure to visit the NAMC radio at www.namcnewswire.com/namcradio for the latest reports, interviews and corporate updates featured on the NAMC Newswire.